However, while the expression on effector T cells is low at a resting state, it is dramatically upregulated upon activation of the T-cell receptor, which may contribute to expanding tumor-specific CD8+/CD25+ T cells and to a better antitumor efficacy [25]. The gene discussed is IL2RA; the disease is neoplasm.